Professor Stupp is an internationally recognized medical oncologist with a special focus on innovative cancer treatments. He is leading the Division of Neuro-Oncology, and serving as the Co-Director of the Malnati Brain Tumor Institute and Associate Director for the Lurie Comprehensive Cancer Center of Northwestern University in Chicago.
Dr. Stupp has been the lead investigator for numerous clinical trials from first-in-human phase 1 to pivotal phase 3 registration studies. In the brain tumor field, he is best known for his contributions of temozolomide (Temodal®) and radiation in the first line treatment of brain tumors (the “stupp protocol”), and establishing MGMT as a predictive marker for benefit from alkylating agent chemotherapy in collaboration with Monika Hegi. He was also the lead investigator establishing Tumor Treating Fields (Optune®) as an innovative treatment modality, both are part of modern standard of care for patients with glioblastoma. Ongoing research is focusing on overcoming the protective blood-brain barrier using innovative technologies that facilitate novel medicines (including immunotherapy) to reach tumor in higher concentrations.
MD: University of Zürich Medical School, Zürich, Switzerland
Fellowship (medicine and hematology/oncology): University of Chicago Hospitals and Cancer Center, Chicago, Illinois
Multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers. Metabolic imaging (PET).
Disclosures of potential Conflict of Interest:
Dr. Stupp serves as an advisor to AstraZeneca, CarThera SARL, Celularity Inc, Craniovation, GT Medical Technology Inc, Insightec Inc, Novocure, Northwest Biotherapeutics Inc, TriAct Therapeutics.